地塞米松不能防止白血病患者卵巢移植后恶性细胞再引入:异种移植模型评估白血病细胞传播风险
该实验研究将11例急性淋巴细胞白血病(ALL)患者的卵巢皮质碎片随机分为地塞米松(DXM)孵育组和对照组,移植至22只免疫缺陷小鼠并监测6个月;DXM孵育未能防止白血病细胞再引入,作者建议在更安全系统开发前谨慎进行白血病患者卵巢组织再移植。
要点
- DXM孵育不能防止卵巢组织再移植后白血病细胞再引入。
- PCR在5例DXM处理组和1例对照组卵巢移植物中检出ALL转移细胞。
- 作者建议在更安全系统开发前谨慎进行白血病患者卵巢组织再移植。
核心结论
- DXM孵育不能防止卵巢组织再移植后白血病细胞再引入。
- 作者认为在更安全系统开发前,应谨慎进行白血病患者卵巢组织再移植,因卵巢移植物中的白血病细胞在冻存和异种移植后能够存活、增殖和迁移。
研究设计与样本
- 实验研究:11例ALL患者卵巢皮质碎片随机分配至DXM孵育组或对照组(每组n=11),移植至22只免疫缺陷小鼠并监测6个月。
- 平行实验:22只免疫缺陷雌性小鼠腹腔注射不同剂量RCH-ACV ALL细胞(10^3至5×10^6,每组n=4),维持4个月。
主要发现
- PCR在5例DXM处理组和1例对照组人卵巢组织移植物中检出ALL转移细胞,并在1例对照小鼠肝脏中检出;6个月后组织学未在任何样本中检出恶性细胞浸润。
- 微小残留病存在于3例DXM处理组和3例对照组小鼠中。
- 注射低至10^3个RCH-ACV细胞后即可在肝脏和脾脏样本中检出该细胞,但仅接受5×10^6个细胞的动物出现疾病临床体征和转移。
关键数值与推荐
- DXM体外孵育浓度为0.4 μM,对照为基础培养基。
- RCH-ACV细胞注射剂量范围为10^3至5×10^6,每组n=4。
临床怎么用
- 作者认为在更安全系统开发前,应谨慎进行白血病患者卵巢组织再移植。
局限性
- 这是一项实验研究,人卵巢组织中白血病细胞的恶性潜能是在免疫缺陷小鼠中评估的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does dexamethasone (DXM) incubation avoid the reintroduction of leukemic malignant cells after ovarian tissue retransplantation in vivo? SUMMARY ANSWER: DXM incubation prior to retransplantation of ovarian tissue does not prevent reintroduction of leukemic cells. WHAT IS KNOWN ALREADY: Retransplantation of cryopreserved ovarian cortex from patients diagnosed with acute lymphoblastic leukemia (ALL) involves a risk of reintroducing malignant cells. DXM treatment is effective at inducing leukemic cell death in vitro. STUDY DESIGN, SIZE, DURATION: This was an experimental study where ovarian cortex fragments from patients with ALL were randomly allocated to incubation with or without DXM (n = 11/group) and grafted to 22 immunodeficient mice for 6 months. In a parallel experiment, 22 immunodeficient mice were injected i.p. with varying amounts of RCH-ACV ALL cells (human leukemia cell line) and maintained for 4 months. PARTICIPANTS/MATERIALS, SETTING, METHODS: Cryopreserved ovarian fragments from patients with ALL were exposed in vitro to 0.4 μM DXM or basal media (control) prior to xenograft into ovariectomized severe combined immunodeficiency (SCID) mice (experiment 1). After 6 months of monitoring, leukemia cell contamination was assessed in ovarian grafts and mouse organs by histology, PCR (presence of mouse mtDNA and absence of p53 were together considered a negative result for the presence of human cells) and detection of immunoglobulin monoclonality and specific ALL markers if present in the patient.In experiment 2, a series of 22 immunodeficient female mice was injected with specific doses of the leukemia cell line RCH-ACV (103 - 5 × 106, n = 4/group) to assess the engraftment competence of the SCID model. MAIN RESULTS AND THE ROLE OF CHANCE: ALL metastatic cells were detected, by PCR, in five DXM-treated and one control human ovarian tissue graft as well as in a control mouse liver, although malignant cell infiltration was not detected by histology in any sample after 6 months. In total, minimal residual disease was present in three DXM-treated and three control mice.RCH-ACV cells were detected in liver and spleen samples after the injection of as little as 103 cells, although only animals receiving 5 × 106 cells developed clinical signs of disease and metastases. LIMITATIONS, REASONS FOR CAUTION: This is an experimental study where the malignant potential of leukemic cells contained in human ovarian tissues has been assessed in immunodeficient mice. WIDER IMPLICATIONS OF THE FINDINGS: These results indicate that DXM incubation prior to retransplantation of ovarian tissue does not prevent reintroduction of leukemic cells. Therefore, caution should be taken in retransplanting ovarian tissue from patients with leukemia until safer systems are developed, as leukemic cells present in ovarian grafts were able to survive, proliferate and migrate after cryopreservation and xenograft. STUDY FUNDING/COMPETING INTEREST(S): Funded by the Regional Valencian Ministry of Education (PROMETEO/2018/137) and by the Spanish Ministry of Economy and Competitiveness (PI16/FIS PI16/01664 and PTQ-16-08222 for S.H. participation). There are no competing interests.
引用
- Díaz-García C, Herraiz S, Such E, et al. Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model. Hum Reprod. 2019. PMID: 31339993. doi:10.1093/humrep/dez115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。